Loading
Life sciences · Journal article
Next Materials · September 19, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Cancer remains a major global public health burden, necessitating the development of novel, targeted therapeutic strategies. Capsaicin, a bioactive vanilloid from chili peppers (Capsicum annuum), demonstrates multifaceted antineoplastic activity via TRPV1 activation, intracellular calcium overload, reactive oxygen species (ROS) generation, and inhibition of oncogenic survival pathways. However, its clinical utility is severely hindered by poor aqueous solubility, rapid first-pass metabolism, pungency-induced irritation, and off-target sensory toxicity. Nanotechnology-based delivery platforms including lipid nanocarriers, polymeric nanoparticles, and stimuli-responsive hybrids help overcome these biopharmaceutical limitations by improving stability, prolonging circulation half-life, and promoting tumor-targeted delivery. In preclinical models, capsaicin nanoencapsulation has shown reduced IC₅₀ values, extends drug release duration, and synergizes with conventional chemotherapeutics to overcome multidrug resistance. Despite these promising preclinical outcomes, systemic clinical translation is impeded by real-world hurdles, including human tumor EPR heterogeneity, potential systemic cardiovascular reflex toxicities, and cGMP manufacturing scale-up complexities. Future development may benefit from adopting emerging paradigms namely artificial intelligence (AI)-assisted formulation design, microfluidic synthesis, and biomarker-stratified personalized medicine to successfully translate capsaicin nanoplatforms into multimodal cancer regimens.